BMS HAS ANNOUNCED* THAT THE MARKETING AUTHORISATIONS FOR DAKLINZA® (DACLATASVIR) WILL BE WITHDRAWN OR WILL BE ALLOWED TO LAPSE IN COUNTRIES WHERE THE PRODUCT NO LONGER IS ROUTINELY PRESCRIBED OR WHERE THERE ARE OTHER THERAPEUTIC OPTIONS AVAILABLE.

As of 16 March 2020, in addition to the 112 countries within the licensed territory, generics can now sell in:

Albania, Armenia, Belarus, Bosnia, Bulgaria, Chile, Colombia, Egypt, Jordan, Kazakhstan, Kosovo, Kyrgyz Republic, Lebanon, Macedonia, Malaysia, Mexico, Moldova, Montenegro, Peru, Romania, Serbia, Thailand, Tajikistan, Ukraine, Uruguay, and Venezuela.

*MPP announcement can be found here: https://medicinespatentpool.org/mpp-media-post/affordable-versions-of-hepatitis-c-medicine-daclatasvir-soon-available-in-additional-countries/
Note: Each triangle represents a manufacturer and timelines represent date of filing.

5 MPP LICENSEES HAVE DEVELOPED DAC 30/60 MG, OF WHICH, 3 COMPANIES ARE READY TO SUPPLY

Licensees Approved*: Cipla, Hetero, Mylan

2 licensees awaiting WHO-PQ approval

Data as of June 2020
Generic DAC has been approved in 34 countries and filed in additional 22 countries. Filings have occurred in 56 countries overall where 47.5% PLHCV reside globally.

### APPROVED (34)

**41.6% PLHCV**

- Benin
- India
- Pakistan
- Cambodia
- Indonesia
- Philippines
- Cameroon
- Kazakhstan
- Tanzania
- Chad
- Kyrgyzstan
- Turkmenistan
- Liberia
- Uganda
- Congo, Rep.
- Libya
- Ukraine
- Côte d’Ivoire
- Malawi
- Uzbekistan
- Dominican Republic
- Malaysia
- Vietnam
- Eswatini
- Mongolia
- Zambia
- Ethiopia
- Myanmar
- Zimbabwe
- Gabon
- Nicaragua
- Guyana
- Nigeria

### FILED (22)

**5.9% PLHCV**

- Azerbaijan
- Kenya
- Bolivia
- Namibia
- Botswana
- Nepal
- Burkina Faso
- Paraguay
- Burundi
- Rwanda
- Costa Rica
- Senegal
- Georgia
- Sri Lanka
- Ghana
- Sudan
- Guatemala
- Suriname
- Haiti
- Thailand
- Honduras
- Togo

---

1. New filings and approvals in green vis-à-vis last update (Q1-20)
2. Countries not included in DAC 30mg & 60mg licence but supply by MPP licensees permitted if no patent is being infringed in that country (*)
3. Countries where DAC 30mg & 60mg has been sold indicated in **bold type**

**Note:** Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

#: Estimated Global PLHCV population till Dec 2019 is 62M as per CDA Foundation data

Data as of June 2020
MPP licensees have sold more than 965,000 treatments* of generic DAC 30/60mg across 28 countries, in which 40% of PLHCV reside globally.

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions.

#: Estimated Global PLHCV population till Dec 2019 is 62M as per POLARIS Data

*Note: 1 HCV treatment = 12 weeks therapy (3 packs)
Non-identified countries are a result of sales made through procurement agencies. Others include countries in which fewer than 5,000 treatments were sold: Cambodia, Azerbaijan, Nigeria, Kyrgyzstan, Armenia, Turkmenistan, Nepal, Bangladesh, Mongolia, Cameroon, Congo, Laos, Bolivia, Sri Lanka, Timor-Leste, South Africa, Zimbabwe, Mauritius.

Data as of June 2020
Daclatasvir has been commercialised in **28** countries by MPP licensees.

More than **965,000** treatments* have been made available till June 2020.

**83%** decline in average price per treatment (DAC 60mg) between 2016 to Q2-2020.

---

**Volumes vs. Price of Generic Daclatasvir Sales**

*Note: 1 HCV treatment = 12 weeks therapy (3 packs)*

Data as of June 2020
DAC/SOF (daclatasvir/sofosbuvir): FORMULATION DEVELOPMENT TIMELINES

2 MPP LICENSEES HAVE DEVELOPED DAC/SOF, OF WHICH 1 COMPANY (CIPLA) IS READY TO SUPPLY THE PRODUCT

Licensees Approved by WHO: Cipla (co-pack)

Approved in 9 countries and filed in additional 12 countries

Note: Each triangle represents a manufacturer and timelines represent date of filing
Generic DAC/SOF has been approved in 9 countries and filed in additional 12 countries. Filings have occurred where 31.9% of PLHCV reside globally.

<table>
<thead>
<tr>
<th>APPROVED (9)</th>
<th>15.6% PLHCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Côte d'Ivoire</td>
<td>Myanmar</td>
</tr>
<tr>
<td>Eswatini</td>
<td>Nicaragua</td>
</tr>
<tr>
<td>India</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Libya</td>
<td>Uganda</td>
</tr>
<tr>
<td>Malawi</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FILED (12)</th>
<th>16.3% PLHCV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For confidentiality purposes, the list of filed countries will be disclosed when more than one approval from stringent regulatory authorities (SRAs) is granted.

---

1. New filings and approvals in green vis-à-vis last update (Q1-20)
2. Countries where DAC/SOF has been sold indicated in bold type

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

# Estimated Global PLHCV population till Dec 2019 is 62M as per POLARIS Data

Data as of June 2020
MPP licensees have supplied more than 70,000 packs* of generic DAC/SOF across: Cambodia, Ethiopia, India, Laos, Myanmar, Uganda & Vietnam.
THANK YOU